2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Potassium Channel
  5. Potassium Channel Control

Potassium Channel Control

Potassium Channel Controls (9):

Cat. No. Product Name Effect Purity
  • HY-100607A
    Landiolol hydrochloride
    		Control 99.96%
    Landiolol (ONO1101) hydrochloride is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol hydrochloride specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol hydrochloride inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol hydrochloride has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol hydrochloride can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury.
  • HY-105559
    Viquidil
    		Control
    Viquidil (Quinotoxine), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil shows antithrombotic activity.
  • HY-117283
    rel-Aprikalim
    		Control
    rel-Aprikalim (rel-RP 52891) is the relative configuration of Aprikalim (HY-121183). Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes.
  • HY-W420344
    Dehydroindapamide
    		Control
    Dehydroindapamide is the indole form of Indapamide (HY-B0259). Dehydroindapamide standard can be used to quantitatively measure the Indapamide turnover rate by CYP3A4, which was approximately 10-fold higher than that of Indoline (HY-Y0788), and slightly enhanced affinity for CYP3A4.
  • HY-100607
    Landiolol
    		Control
    Landiolol (ONO1101) is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury.
  • HY-158936
    Lumula
    		Control
    Lumula (Maxeyprost) is an ethyl amide derivative of Unoprostone (HY-106916).
  • HY-100607AR
    Landiolol hydrochloride (Standard)
    		Control
    Landiolol (ONO1101) hydrochloride (Standard) is the analytical standard of Landiolol hydrochloride (HY-100607A). This product is intended for research and analytical applications. Landiolol (ONO1101) hydrochloride is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol hydrochloride specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol hydrochloride inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol hydrochloride has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol hydrochloride can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury.
  • HY-W420344R
    Dehydroindapamide (Standard)
    		Control
    Dehydroindapamide (Standard) is the analytical standard of Dehydroindapamide. This product is intended for research and analytical applications. Dehydroindapamide is the indole form of Indapamide (HY-B0259). Dehydroindapamide standard can be used to quantitatively measure the Indapamide turnover rate by CYP3A4, which was approximately 10-fold higher than that of Indoline (HY-Y0788), and slightly enhanced affinity for CYP3A4.
  • HY-18172B
    (-)-KCC2 blocker 1
    		Control 99.19%
    (-)-KCC2 blocker 1 is an enantiomer of KCC2 blocker 1 (HY-18172). KCC2 blocker 1 (compound 13) is an orally active and selective K+-Cl- cotransporter KCC2 blocker with an IC50 of 1 μM.